Browse NKX2-2

Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00046 Homeobox domain
Function

Acts as a transcriptional activator. Required for the maintenance of NEUROD1 expression in the horomone-producing endocrine cells of the pancreas. May be involved in specifying diencephalic neuromeric boundaries, and in controlling the expression of genes that play a role in axonal guidance. Associates with chromatin at the NEUROD1 promoter region. Binds to a subset of consensus elements within the NEUROD1 promoter (By similarity).

> Gene Ontology
 
Biological Process GO:0001708 cell fate specification
GO:0001709 cell fate determination
GO:0002064 epithelial cell development
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002066 columnar/cuboidal epithelial cell development
GO:0002067 glandular epithelial cell differentiation
GO:0002068 glandular epithelial cell development
GO:0003002 regionalization
GO:0003309 type B pancreatic cell differentiation
GO:0003310 pancreatic A cell differentiation
GO:0003312 pancreatic PP cell differentiation
GO:0003323 type B pancreatic cell development
GO:0003326 pancreatic A cell fate commitment
GO:0003327 type B pancreatic cell fate commitment
GO:0003329 pancreatic PP cell fate commitment
GO:0007224 smoothened signaling pathway
GO:0007389 pattern specification process
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009953 dorsal/ventral pattern formation
GO:0010001 glial cell differentiation
GO:0010720 positive regulation of cell development
GO:0010721 negative regulation of cell development
GO:0014003 oligodendrocyte development
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0021510 spinal cord development
GO:0021511 spinal cord patterning
GO:0021513 spinal cord dorsal/ventral patterning
GO:0021514 ventral spinal cord interneuron differentiation
GO:0021515 cell differentiation in spinal cord
GO:0021517 ventral spinal cord development
GO:0021522 spinal cord motor neuron differentiation
GO:0021529 spinal cord oligodendrocyte cell differentiation
GO:0021530 spinal cord oligodendrocyte cell fate specification
GO:0021545 cranial nerve development
GO:0021554 optic nerve development
GO:0021675 nerve development
GO:0021778 oligodendrocyte cell fate specification
GO:0021779 oligodendrocyte cell fate commitment
GO:0021780 glial cell fate specification
GO:0021781 glial cell fate commitment
GO:0021782 glial cell development
GO:0021953 central nervous system neuron differentiation
GO:0031016 pancreas development
GO:0031018 endocrine pancreas development
GO:0032570 response to progesterone
GO:0034284 response to monosaccharide
GO:0035270 endocrine system development
GO:0035883 enteroendocrine cell differentiation
GO:0042063 gliogenesis
GO:0045165 cell fate commitment
GO:0045665 negative regulation of neuron differentiation
GO:0045666 positive regulation of neuron differentiation
GO:0045685 regulation of glial cell differentiation
GO:0045687 positive regulation of glial cell differentiation
GO:0048545 response to steroid hormone
GO:0048565 digestive tract development
GO:0048663 neuron fate commitment
GO:0048664 neuron fate determination
GO:0048665 neuron fate specification
GO:0048708 astrocyte differentiation
GO:0048709 oligodendrocyte differentiation
GO:0048713 regulation of oligodendrocyte differentiation
GO:0048714 positive regulation of oligodendrocyte differentiation
GO:0050768 negative regulation of neurogenesis
GO:0050769 positive regulation of neurogenesis
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051961 negative regulation of nervous system development
GO:0051962 positive regulation of nervous system development
GO:0055123 digestive system development
GO:0060579 ventral spinal cord interneuron fate commitment
GO:0060580 ventral spinal cord interneuron fate determination
GO:0060581 cell fate commitment involved in pattern specification
GO:0060582 cell fate determination involved in pattern specification
GO:0072148 epithelial cell fate commitment
GO:1901654 response to ketone
Molecular Function GO:0001159 core promoter proximal region DNA binding
GO:0003682 chromatin binding
GO:0003713 transcription coactivator activity
GO:0008134 transcription factor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-186712: Regulation of beta-cell development
R-HSA-210745: Regulation of gene expression in beta cells
R-HSA-210746: Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NKX2-2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NKX2-2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NKX2-2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4970.357
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5710.499
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4620.531
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5730.55
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.7820.28
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9710.572
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.8960.358
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2780.391
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-3.0370.0868
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.570.351
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.570.502
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6480.00118
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NKX2-2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NKX2-2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NKX2-2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NKX2-2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NKX2-2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NKX2-2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NKX2-2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNKX2-2
NameNK2 homeobox 2
Aliases NKX2.2; NKX2B; NK-2 (Drosophila) homolog B; NK2 transcription factor related, locus 2 (Drosophila); NK2 tran ......
Chromosomal Location20p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NKX2-2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.